(Q37306729)

19 August 2017

1 reference

title

When is antipsychotic polypharmacy supported by research evidence? Implications for QI. (English)

1 reference

19 August 2017

Jessica L Gören

1

1 reference

19 August 2017

Joseph J Parks

2

1 reference

19 August 2017

Frank A Ghinassi

3

1 reference

19 August 2017

Celeste G Milton

4

1 reference

19 August 2017

John M Oldham

5

1 reference

19 August 2017

Pablo Hernandez

6

1 reference

19 August 2017

Jeffrey Chan

7

1 reference

19 August 2017

Richard C Hermann

8

1 reference

19 August 2017

publication date

1 October 2008

1 reference

Joint Commission Journal on Quality and Patient Safety

19 August 2017

published in

1 reference

19 August 2017

volume

34

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

571-582

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Use of combinations of antipsychotics: McLean Hospital inpatients, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Antipsychotic medication coprescribing in a large state hospital system

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Hospital use of antipsychotic drugs: polytherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Antipsychotic drug use: McLean Hospital, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Patterns of antipsychotic utilization in a tertiary care psychiatric institution

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Polypharmacy in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Long-term combination antipsychotic treatment in VA patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Combination antipsychotic therapy in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Multiple antipsychotic medication prescribing patterns

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Pharmacy costs: finding a role for quality.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

High-cost use of second-generation antipsychotics under California's Medicaid program

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Managed care: improving psychiatric drug benefit management: I. Lessons from Massachusetts.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Adherence to conventional and atypical antipsychotics after hospital discharge.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Public-sector managed behavioral health care: II. Contracting for Medicaid services--the Massachusetts experience

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Managed care: improving psychiatric drug benefit management: III. The VA's approach to atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Clozapine alone versus clozapine and risperidone with refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Clozapine with amisulpride for refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Addition of risperidone to clozapine therapy in chronically psychotic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

An open trial of risperidone augmentation of partial response to clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Clozapine in China: a review and preview of US/PRC collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Risperidone added to clozapine: impact on serum prolactin levels.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Antipsychotic polypharmacy does not increase the risk for side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Schizophrenia, neuroleptic medication and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Antipsychotic polypharmacy: do benefits justify the risks?

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Enhancing patient safety in psychiatric settings

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Restraint and seclusion in psychiatric inpatient wards

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

Cost of antipsychotic polypharmacy in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934072-0

7 January 2021

10.1016/S1553-7250(08)34072-0

Identifiers

DOI

1 reference

19 August 2017

1 reference